Meno Produktu:Vapreotid,Octastatin,Vapreotid
Sekvencia: D-Phe-[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH2
Alias:Sanvar,RC-160;VAPREOTIDE;D-PHE-CYS-TYR-D-TRP-LYS-VAL-CYS-TRP-NH2; Octastatin;
FCYWKVCW-NH2;D-Phe-L-Cys(1)-L-Tyr-D-Trp-L-Lys-L-Val-L-Cys(1)-L-Trp-NH2;
Cas č.: 103222-11-3
Molekulárny vzorec: C57H70N1209S2
Molekulová hmotnosť: 1131.40
Čistota (HPLC): 98.0%
Vzhľad: Biely prášok
Jediná nečistota(HPLC): 1.0%
Aminokyselinové zloženie: 10% teoretického
Obsah peptidov(N %): 80%(od %N)
Obsah vody(Karl Fischer): 6.0%
Obsah acetátu(HPIC): 15.0%
Hmotnostná bilancia: 95.0~105,0 %
stupňa : Farmaceutická trieda
Skladovanie: ZATVORENÉ, nižšie 2 ~ 8 ℃ konzervácia
Použitie : Liek sa môže použiť na liečbu včasného akútneho krvácania z pažerákových varixov (EVB) a endoskopická intervenčná liečba pred hemostázou, môže tiež krvácať vo vnútri 5 d šošovka na liečbu a prevenciu recidívy po endoskopickom.vapreotidacetát bude jedinou schválenou liečbou krvácania z pažerákových varixov v USA.
Variceal bleeding is a life-threatening complication of portal hypertension. The recommended treatment includes the early administration of a vasoactive drug. Vapreotide is a somatostatin analogue with a different receptor affinity to octreotide. It decreases portal pressure and blood flow of collateral circulation in rats with cirrhosis. The pivotal study of early administration of vapreotide in patients with cirrhosis and variceal bleeding has shown a significant improvement in bleeding control and, in the subset of patients with significant bleeding, a significant reduction in mortality. Navyše, a meta-analysis of four randomized studies has shown a significant improvement in bleeding control. Vapreotide administrated via the intravenous route is simple to use, with practically no contraindications and few, usually minor, side effects.
The immediate release formulation of Sanvar, a somatostatin analogue, is used in the treatment of acute esophageal variceal bleeding (EVB).Sanvar is used prior to endoscopic intervention to control haemorrhage and prevent re-bleeding during the critical five days following the onset of bleeding. EVB is a life threatening condition and the mortality rate is high (about 15% do 25%) in the first six weeks following the haemorrhage. EVB is the cause of about 70% of gastro-intestinal bleeding in patients suffering from liver cirrhosis.
